Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1BRAF V600E Mutation 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Cobicistat × 1 year × Clear all
NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06610682 2025-12-10

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
15 enrolled

BRAF V600E Mutation

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Constellation Pharmaceuticals

Phase 1/2 Completed
175 enrolled 23 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡